Loading...

ENTX ENTERA BIO LTD US FDA Inspections 8-K Filing

NTR

NTX

ENTERA BIO LTD

(ENTX)

2025 8-K

Show Summary

Summary

New Drug Application Agreement

Financial Statements

Financial Results

Collaboration Agreement

Advisory Vote Update

Financial Results

Financial Results Announcement

Annual Meeting Voting Results

Financial Results Announcement

Financial Results Announcement

Compliance Regained

Registration Statement Filed

Extension for Compliance wi...

Private Placement

Earnings Report

Annual Meeting Voting Results

Financial Results Announcement

Appointment of Director

Earnings Report

Earnings Report

External Links:

On July 28, 2025, Entera Bio Ltd. announced that the FDA agreed to use Bone Mineral Density (BMD) as the primary endpoint for their Phase 3 study of EB613 in postmenopausal women with osteoporosis, which supports their New Drug Application.

AI Assistant

ENTERA BIO LTD

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.